TLRY Stock Analysis: Tilray | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 570m USD | 12M Return: -32.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.4M
Qual. Beats: 0
Rev. Trend: 92.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tilray Brands is a lifestyle consumer products company engaged in the research, cultivation, processing, and distribution of medical cannabis products, with operations spanning Canada, the United States, Europe, the Middle East, Africa, and other international markets. The company operates through four reportable segments: Beverage, Cannabis, Distribution, and Wellness, reflecting a business model that has expanded well beyond its original cannabis-focused roots.
The companys product portfolio spans medical and adult-use cannabis, pharmaceutical and wellness products, beverage products, and hemp-based food items. Tilray markets its offerings under a wide range of brands, including Tilray, Aphria, Broken Coast, Charlottes Web, Manitoba Harvest, and a sizeable portfolio of craft beer labels such as SweetWater Brewing, Montauk Brewing, Breckenridge Brewery, and Shock Top. Despite this diversified consumer products profile, the company is classified under the GICS Health Care sector in the Pharmaceuticals sub-industry, and the cannabis industry remains heavily regulated, with cross-border commerce in THC products between Canada and the U.S. subject to strict federal restrictions.
Tilray sells through a broad set of channels, including retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company is headquartered in Leamington, Canada, and was renamed Tilray Brands, Inc. in January 2022 to reflect its broader lifestyle consumer products positioning.
- German medical cannabis legalization drives international revenue growth
- Canadian cannabis pricing pressure compresses segment margins
- US federal rescheduling could unlock major market expansion
| Net Income: -1.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -2.25 > 1.0 |
| NWC/Revenue: 39.02% < 20% (prev 53.43%; Δ -14.41% < -1%) |
| CFO/TA -0.03 > 3% & CFO -55.8m > Net Income -1.85b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.7m) vs 12m ago 24.05% < -2% |
| Gross Margin: 27.67% > 18% (prev 30.83%; Δ -3.16% > 0.5%) |
| Asset Turnover: 33.82% > 50% (prev 23.32%; Δ 10.49% > 0%) |
| Interest Coverage Ratio: -67.61 > 6 (EBIT TTM -1.96b / Interest Expense TTM 28.9m) |
| A: 0.22 (Total Current Assets 718.8m - Total Current Liabilities 257.5m) / Total Assets 2.07b |
| B: -2.37 (Retained Earnings -4.92b / Total Assets 2.07b) |
| C: -0.56 (EBIT TTM -1.96b / Avg Total Assets 3.50b) |
| D: 2.84 (Book Value of Equity 1.56b / Total Liabilities 549.1m) |
| Altman-Z'' = -7.05 = D |
| DSRI: 0.77 (Receivables 118.4m/149.3m, Revenue 1.18b/1.15b) |
| GMI: 1.11 (GM 30.83% / 27.67%) |
| AQI: 1.02 (AQ_t 0.64 / AQ_t-1 0.64) |
| SGI: 1.03 (Revenue 1.18b / 1.15b) |
| TATA: -0.86 (NI -1.85b - CFO -55.8m) / TA 2.07b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 4.46 with a total of 3,764,291 shares traded. Over the past week, the price has changed by +1.83%, over one month by -10.98%, over three months by -33.63% and over the past year by -32.42%.
Current recommended Stop Loss: 4.10 (which is 8.1% or 1.4 ATR below the current price).
Tilray has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold TLRY.
- StrongBuy: 4
- Buy: 0
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10 | 125.1% |
P/E Forward = 1000.0
P/S = 0.6646
P/B = 0.367
Revenue TTM = 1.18b USD
EBIT TTM = -1.96b USD
EBITDA TTM = -1.84b USD
Long Term Debt = 223.2m USD (from longTermDebt, last quarter)
Short Term Debt = 33.5m USD (from shortTermDebt, last quarter)
Debt = 384.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 67.5m
Net Debt = 164.7m USD (calculated: Debt 384.6m - CCE 219.9m)
Enterprise Value = 735.1m USD (570.4m + Debt 384.6m - CCE 219.9m)
Interest Coverage Ratio = -67.61 (Ebit TTM -1.96b / Interest Expense TTM 28.9m)
EV/FCF = -7.68x (Enterprise Value 735.1m / FCF TTM -95.7m)
FCF Yield = -13.02% (FCF TTM -95.7m / Enterprise Value 735.1m)
FCF Margin = -8.10% (FCF TTM -95.7m / Revenue TTM 1.18b)
Net Margin = -156.2% (Net Income TTM -1.85b / Revenue TTM 1.18b)
Gross Margin = 27.67% ((Revenue TTM 1.18b - Cost of Revenue TTM 854.9m) / Revenue TTM)
Gross Margin QoQ = 26.58% (prev 26.43%)
Tobins Q-Ratio = 0.35 (Enterprise Value 735.1m / Total Assets 2.07b)
Interest Expense / Debt = 7.52% (Interest Expense 28.9m / Debt 384.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.54b (EBIT -1.96b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.79 (Total Current Assets 718.8m / Total Current Liabilities 257.5m)
Debt / Equity = 0.25 (Debt 384.6m / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = -0.09 (negative EBITDA) (Net Debt 164.7m / EBITDA -1.84b)
Debt / FCF = -1.72 (negative FCF - burning cash) (Net Debt 164.7m / FCF TTM -95.7m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = -52.82% (Net Income -1.85b / Total Assets 2.07b)
RoE = -92.82% (Net Income TTM -1.85b / Total Stockholder Equity 1.99b)
RoCE = -88.41% (EBIT -1.96b / Capital Employed (Equity 1.99b + L.T.Debt 223.2m))
RoIC = -86.23% (negative operating profit) (NOPAT -1.54b / Invested Capital 1.79b)
WACC = 10.44% (E(570.4m)/V(955.0m) * Re(13.48%) + D(384.6m)/V(955.0m) * Rd(7.52%) * (1-Tc(0.21)))
Discount Rate = 13.48% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 98.76 | Cagr: 21.22%
[DCF] Fair Price = unknown (Cash Flow -95.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.39 | # QB: 0
Revenue Correlation: 92.39 | Revenue CAGR: 12.70% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-08-31): EPS=-0.14 | Chg30d=+3.57% | Revisions=-25% | Analysts=4
EPS current Year (2026-05-31): EPS=-0.08 | Chg30d=N/A | Revisions=-25% | GrowthEPS=-179.1% | GrowthRev=+7.4%
EPS next Year (2027-05-31): EPS=-0.39 | Chg30d=-13.98% | Revisions=-50% | GrowthEPS=+38.9% | GrowthRev=+24.0%
[Analyst] Revisions Ratio: -62% (up=0, down=5)